natgillin/translations-raw huggingface dataset:
aborting the transaction, based on detecting the program exception condition; 
prekidanje transakcije na osnovi detektiranja stanja izuzimanja programa;
The method of treating or preventing of claim 1, wherein said sugar and/or sugar alcohol is a combination of sucrose and mannitol. 
Formulacija iz patentnog zahtjeva 6, pri čemu šećer i/ili šećerni alkohol obuhvaćaju sukrozu i manitol.
The pressurized metered dose inhaler as claimed in claim 5 or 6, wherein the dose of beclometasone dipropionate is 50 or 100 microg. 
Inhalator sa stlačenim inhalatom kako je prijavljen u patentnom zahtjevu 5 ili 6, naznačen time da je doza beklametazon-dipropionata 550 ili 100 mg.
It is a recommended practice to maintain opioid-dependence in pregnant women with synthetic opioids. 
Preporučena praksa je održavati opioidnu ovisnost kod trudnih žena sintetičkim opioidima.
reacting an intermediate of formula (XXIV) with lithium aluminium hydride in a suitable solvent, to obtain compounds of formula (I) wherein R4 is -CH2-OH, herein referred to as compounds of formula (I-e), with the variables as defined in claim 1; 
HR P20110394 TI sa varijablama kako je definirano u zahtjevu 1; reakciju intermedijera prema formuli (XXIV) sa litij aluminij hidridom u prikladnom otapalu, da se dobiju spojevi prema formuli (1) pri čemu R" je -CHb-OH, a ovdje se nazivaju spojevi formule (I-e),
is a heteroaryl ring represented by the formula D1-D2 
R' je heteroarilni prsten predstavljen formulom DID? o
• the viral envelopes are entirely derived from influenza viral particles, 
* virusni omotači su u cijelosti dobiveni od virusnih čestica gripe,
respectively and independently represents an unsubstituted C1-8 alkyl group, an unsubstituted C2-8 alkenyl group, an unsubstituted C2-8 alkynyl group, a hydroxyl group, a halogeno group, a cyano group or a nitro group; 
C2-8-alkinilnu skupinu, nesupstituiranu C3-8-cikloalkilnu skupinu, nesupstituiranu C4-8-cikloalkenilnu skupinu, nesupstituiranu C6-10-arilnu skupinu, nesupstituiranu heterocikličku skupinu, nesupstituiranu
The reaction mixture was filtered and evaporated and the residue treated with a solution of maleic acid (22 g) in ethanol (100 ml). 
Reakciona smjesa se filtrira i ispari i ostatak se tretira s otopinom maleinske kiseline (22 g) u etanolu (100 ml).
transferring the contents of the biopolymer mixture of step n to the mixing vessel of step i with continuous stirring at 10 to 50 RPM and homogenizing the mixture at 1000 to 3000 RPM under inert gas flushing and under vacuum of minus 1000 to minus 300 mm of mercury, said inert gas being preferably nitrogen, 
prenošenje sadržaja smjese biopolimera iz stupnja n u posudu za miješanje iz stupnja i uz kontinuirano miješanje pri 10 do 50 okretaja u minuti i homogeniziranje smjese pri 1000 do 3000 okretaja u minuti, uz propuhivanje inertnim plinom i pod vakuumom od minus 1000 do minus 300 mm stupca žive, kod čega je navedeni inertni plin prvenstveno dušik,
In the first embodiment according to the present invention, the actuation member 17 is pressed down and rotated relative to the housing or locking element 18 by an angle of about 90° for switching between the discharge state and the non-discharge state and vice versa. 
U prvoj izvedbi prema predloženom izumu, za prebacivanje između stanja pražnjenja i stanja ne-pražnjenja i obratno element za pokretanje 17 se okreće u odnosu na kućište ili u odnosu na element za zabravljivanje 18 za kut od približno 90".
the pendulum (4) supports the first and second axes (A 1; A 2) of the first and second cog wheels (12; 22) and of the first and second eccentric elements (14; 24); 
poluga (4) podupire osovine (A1; A2) zupčanika (12; 22) i ekscentričnih elemenata (14; 24);
The use according to claim 7, wherein said salt is the B form of the DL-lactic acid addition salt characterised by XRPD reflections at 6.01, 10.10, 10.32, 12.06, 12.84, 13.08 and 13.58 (°2θ). 
Uporaba u skladu s patentnim zahtjevom 7, pri čemu je navedena sol B oblik dodatne soli DL-mliječne kiseline karakterizirana XRPD refleksijama na 6.01, 10.10, 10.32, 12.06, 12.84, 13.08 i 13.58 (°2Ѳ).
The second yam is knit in every wale in an area at the rear of the leg adapted to engage the calf of the wearer, the calf area thereby having a nonrib appearance. 
Drugi konac se plete na svakom kraju u području stražnjeg dijela noge, koji je prilagođen tako da zahvati list nosioca, pri čemu područje lista zbog toga ima izgled bez rebra.
DNA was isolated and sequenced. 
DNA se izolira i sekvencionira.
A compound of Claim 3 wherein J is J-29, and the 3-position of J-29 is connected to Z1 and the 5-position of J-29 is connected to R5; 
Tvar iz patentnog zahtjeva 3, pri čemu J je J-29, i 3-pozicija od J-29 je povezana sa Z1 i 5-pozicija oa J-29 je povezana s R5;
An impact attenuator according to any of the preceding claims, characterized in that the pins (13) and the elongated draw element (14) are located such that the elongated draw element will have a change of direction of at least 135° at respective passage of the at least two pins. 
Prigušivač udara prema bilo kojem od prethodnih zahtjeva, naznačen time da su klinovi (13) i duguljasti izvlačivi element (14) smješteni tako da će duguljasti izvlačivi element imati promjenu smjera od barem 135° kod odgovarajućeg prolaza pored barem dva klina.
Blocking Solution was removed using a plate washer and 200µl of 0.5% Triton X-100 / PBS was added to permeabalise the cells. 
Otopina za blokiranje ukloni se pomoću ispirača mikrotitarskih pločica i doda se 200 ul 0.5% Triton X-100 / PBS radi permeabilizacije stanica.
A bone plate system for securing a bone plate to bone, the system comprising: 
Sustav pločica za kosti za pričvršćivanje pločice za kosti na kost koji obuhvaća: vijak za kosti (600) sa središnjom osi (619);
Apparatus according to claim 1, wherein three spaced apart anvils may be provided and the mitigating strip woven over a side of the first anvil, under a side of the second anvil and over a side of the third anvil. 
Uređaj prema zahtjevu 1, gdje postoje tri međusobno razmaknuta nakovnja i ublažujuća traka se omata oko jedne strane prvog nakovnja, ispod druge strane drugog nakovnja i preko suprotne strane trećeg nakovnja.
A compound according to claim 1, wherein the compound of the formula (Ia″) is a compound of formula (I-T22) 
Spojevi prema zahtjevu 1, naznačeni time da spojevi s formulom (1a") su spojevi s formulom (I-T22)
identifying the human immunoglobulin light chain variable domain amino acid sequence, or encoding nucleotide sequence, from the antibody or two antibodies; and/or 
identifikacije aminokiselinske sekvence varijabilne domene lakog lanca humanog imunoglobulina, iz antitijela ili dva antitijela; i/ili
a single- or multi-layered first decorative ply is applied to a carrier ply; 
jednoslojni ili višeslojni prvi dekorativni sloj (3) nanosi se na nosivi sloj;
adding 1 equivalent 1-iodo-2,4-dimethylbenzene, 0.8-1.2 equivalent 2-bromo thiophenol and 1-10 equivalents piperazine to Mixture A to obtain Mixture B; and 
dodavanja 1 ekvivalenta 1-jod-2,4-dimetilbenzena, 0,8-1,2 ekvivalenta 2-bromtiofenola i 1-10 ekvivalenata piperazina u smjesu A kako bi se dobilo smjesu B; i
General Synthetic Scheme for Quinoxalinones where Y= Covalent Bond 
Opća sintetska shema za kinoksalinone gdje je Y= kovalentna veza
Use according to any one of claims 10, 18 and 19 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia. 
Uporaba sukladno bilo kojem od patentnih zahtjeva 11, 19 120, naznačena time, da se koristi za liječenje bolesnika koji pate od prijašnjeg srčanog stanja ili stanja koje može biti pogoršano tahikardijom.
Cutter-suction dredger according to claim 7, characterised in that both the extension piece (10) and the cutting arm (3) are provided with a flange (17, 19) to be able to reversibly couple the two together. 
Jaružalo sa sječenjem i usisavanjem u skladu s patentnim zahtjevom 7, naznačen time što i dio za produljivanje (10) i sječivni krak (3) imaju prirubnicu (17,19) koja omogućuje odvojivo spajanje ta dva dijela zajedno.
They may be further modified to enhance swelling and permeability by the incorporation of materials such as water soluble cellulose ethers and starches in order to ensure complete disintegration/dissolution of the film. 
Nadalje, isti mogu biti modificirani s ciljem povećanja bubrenja i permeabilnosti ugradnjom materijala kao što su u vodi topljivi eteri celuloze 1 škrob, čime se osigurava potpuna razgradnja/topljivost filma. HR P20090104 T3
The vinylamide polymer concentration can also be less than about 2.5 weight % of the total reaction mixture, and the vinylamide polymer can have an average molecular weight of about 100,000 to about 1,500,000 Daltons. 
(b) manje od 2,5%, težinski, od ukupne reakcijske smjese, te ima prosječnu molekulsku težinu od 100.000 do 1.500.000 Da.
a 5-6 membered saturated or partially unsaturated cycloalkyl ring; and R12 is hydrogen and R3 is H, Br, Cl, SR6, OR6, aryl, heteroaryl, or C1-C6 alkyl, wherein said aryl is optionally substituted with Cl and said alkyl is optionally substituted with C(O)OR8, NR8R9, or OR8. 
5-6-eročlani zasićeni ili djelomično nezasićeni cikloalkil prsten; i je vodik i R3 je H, Br, Cl, SR6, OR6, aril, heteroaril, ili C1-C6 alkil, gdje je taj aril po izboru supstituiran s Cl i taj alkil je po izboru supstituiran s C(O)OR8, NR8R9 ili OR8.
The invention is directed to novel pyrrolopyrimidine compounds of formula (I) 
Spoj, naznačen time, da ima formulu (I):
The method according to claim 1, wherein the papillary renal cell carcinoma is hereditary type I papillary renal cell carcinoma. The method according to claim 1, wherein the papillary renal cell carcinoma is hereditary type II papillary renal cell carcinoma. 
CCI-779, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se uznapredovali papilarni karcinom bubrežnih stanica bira između nasljednog papilarnog karcinoma bubrežnih stanica tip I, nasljednog papilarnog karcinoma bubrežnih stanica tip II i sporadičnog papilarnog karcinoma bubrežnih stanica.
More details about the connection of the outputs of the receiver, to the electronic controls of the boat, are provided in FIG. 4 . 
Više pojedinosti o priključivanju izlaza prijemnika na elektroničke kontrole plovila je prikazano na Slici 4.
reacting a compound of Formula X with a compound of Formula XI hal-(CH2)n-OP1 Formula XI to form a compound of Formula XII; 
reakciju spoja Formule X sa spojem Formule XI hal-(CH2)n-OP1 Formula XI čime se dobiva spoj Formule XII;
the first disconnector pole (214) and the second disconnector pole (215) are rotatable around a rotation axis (252), and wherein 
prvi pol rastavljača (214) i drugi pol rastavljača (215) se mogu okretati oko osi rotacije (252), i time da je
is chosen from the series consisting of hydrogen and R14; 
R'' se bira iz skupine koju čine vodik i R'*;
The process of claim 12, where the 1,1,1,2,3-pentachloropropane is dehydrochlorinated in the presence of ferric chloride and (i) crude 1,1,1,2,3-pentachloropropane reactor effluent from a reactor in which 1,1,1,2,3- pentachloropropane is formed is dehydrochlorinated directly, without prior purification and without added catalysts or reagents, or (ii) purified 1,1,1,2,3-pentachloropropane is fed to a reactive distillation system and ferric chloride is separately added to the system. 
Postupak iz patentnog zahtjeva 12, pri čemu se 1,1,1,2,3-pentakloropropan dehidroklorira u prisustvu željezovog(IlI) klorida i (1) sirovi 1,1,1,2,3-pentakloropropan koji se izljeva iz reaktora u kojem se 1,1,1,2,3- pentakloropropan stvara izravno se dehidroklorira, bez prethodnog pročišćavanja 1 bez dodavanja katalizatora ili reagencija, ili (1) pročišćeni 1,1,1,2,3-pentakloropropan se dovodi u reaktivni sustav destilacije i željezov(IlI) klorid se zasebno dodaje u sustav.
The soft chewable veterinary composition of claim 1, wherein the pharmaceutically acceptable carrier comprises one or more lubricants. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da farmaceutski prihvatljiv nosač obuhvaća jedno ili više maziva,
is piperidinyl substituted with 1 substituent selected from the group consisting of or R2 is 
je piperidinil supstituiran sa 1 supstituentom izabranim iz grupe koju čine [image] ili R2 je [image] ili [image]
The composition of clause 1 wherein said pharmaceutically acceptable salt is a hydrochloride salt, hydrobromide salt, methanesulfonate, toluenesulfonate, acetate, fumarate, sulfate, bisulfate, succinate, citrate, phosphate, maleate, nitrate, tartrate, benzoate, biocarbonate, carbonate, sodium hydroxide salt, calcium hydroxide salt, potassium hydroxide salt, tromethamine(Tris) salt, or mixtures thereof. The composition of clause 5 wherein said pharmaceutically acceptable salt is a hydrochloride salt, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate, or mixtures thereof. 
Sastav prema zahtjevu 1, naznačeno time da je spomenuta farmaceutski prihvatljiva sol hidrokloridna sol, hidrobromidna sol, metan sulfonat, toluensulfonat, acetat, fumarat, sulfat, bisulfat, sukcinat, citrat, fosfat, maleat, nitrat, tartrat, benzoat, bikarbonat, karbonat, sol natrijevog hidroksida, sol kalcijevog hidroksida, sol kalijevog hidroksida, sol trometamina(Tris), ili mješavine istih, poželjno hidrokloridna sol, metan sulfonat, toluensulfonat, acetat, sukcinat, citrat, maletat, tartrat, ili mješavina istih, a najpoželjnije sol acetata.
Process according to Claim 5, wherein the water-soluble calcium compound is selected from calcium chloride, calcium formate, calcium acetate, calcium hydroxide and/or calcium nitrate. 
Uporaba prema patentnom zahtjevu 4, naznačena time što spoj kalcija topiv u vodi je izabran od kalcij klorida, kalcij acetata, kalcij formata, kalcij hidroksida i/ili kalcij nitrata.
Power to the solenoids 104 and 106 will be activated by the controller 80 for an interval of 30 seconds. 
Napajanje solenoida 105 1 106 aktivira kontrolor 80 u trajanju od 30 s. HR P20060161 T3 u cjevovodima.
of sodium borohydride (NaBH4) was charged to the flask and the reaction stirred in the ice/water bath for five hours. 
natrij borhidrida (NaBHt) je bilo stavljeno u tikvicu i reakcija je bila miješana u kupelji led/voda pet sati.
The formulation according to claim 8, wherein said binder is lactose. 
Formulacija prema zahtjevu 8, naznačena time, da vezivno sredstvo je laktoza.
The composition of any one of the preceding claims, wherein the filler is lactose or a sugar alcohol, such as mannitol, sorbitol, maltitol, erythrol, or a mixture of two or more of these components. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da punilo je laktoza 1li šećerni alkohol, kao što je manitol, sorbitol, maltitol, eritrol, ili mješavina od dva ili više tih spojeva.
a collapsible and expandable annular frame that is configured to be collapsed to a radially collapsed state for mounting on a delivery apparatus and expanded to a radially expanded state inside a patient's body, the frame having an inflow end, an outflow end, and a lumen extending from the inflow end to the outflow end, the frame comprising a plurality of struts defining a plurality of cells; 
Protetski zalistak na bazi katetera (100) konfiguriran da bude prešan do radijalno sklopljenog stanja na balonu uređaja za isporuku koji sadrži: sklopivi i proširivi prstenasti okvir (102), konfiguriran da se sklopi u radijalno sklopljeno stanje za montiranje na aparat za dostavljanje i proširen do radijalno proširenog stanja unutar tijela;
The PD-1 antibody or the antigen-binding fragment thereof according to any one of claims 1-10, wherein the antibody or the antigen-binding fragment is a humanized antibody or a fragment thereof. 
PD-1 protutijelo ili njegov fragment koji se veže na antigen sukladno patentnom zahtjevu 1, pri čemu je to protutijelo ili njegov fragment koji se veže na antigen humanizirano protutijelo. PD-1 protutijelo ili njegov fragment koji se veže na antigen sukladno patentnom zahtjevu 4, pri čemu:
Method according to Claim 13, wherein said provision of said thread reinforcement comprises providing a thread reinforcement web, placing a layer of plastic material on either side of it and fixing said layers of plastic material to each other. Method according to Claim 12, wherein fixing said layers to each other comprises fusing. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što izvedba navedenog pojačanja od vlakana obuhvaća izradu mrežastog pletenog tkanog materijala od vlakana za pojačanje, stavljanje sloja materijala od plastike na njegove obje strane i pričvršćenje navedenih slojeva materijala od plastike jednog na drugi.
The present invention preferably provides a human engineered DKK-1 antibody wherein the human engineered DKK-1 antibody comprises a light chain wherein the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22. 
Ljudsko konstruirano protutijelo protiv DKK-1, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što ljudsko konstruirano protutijelo protiv DKK-I sadrži teški lanac koji ima aminokiselinski slijed sa SEQ ID NO: 18 1 laki lanac koji ima aminokiselinski slijed sa SEQ ID NO: 20.
The counter as claimed in claim 12, wherein said third ring member comprises a limiting mechanism to limit free rotation of said second ring member relative to said third ring member about said common axis. 
Brojač kao što je navedeno u zahtjevu 15, naznačeno time da navedeni treći prstenasti element (1502) sadrži mehanizam ograničenja (1506) za ograničavanje slobodne rotacije navedenog drugog prstenastog elementa (202, 1510) u odnosu na navedeni treći prstenasti element oko navedene zajedničke osi.
The method according to claim 1, wherein A1 represents a hydrogen atom or a methyl group. 
Spoj formule (1) u skladu s patentnim zahtjevom 1, naznačen time, da A1 predstavlja atom vodika ili metilnu skupinu.
The method of claim 1, wherein the plurality of resource sets comprise a plurality of component carriers, the control channel on at least one of the plurality of search spaces being distributed over the component carriers, and wherein the secondary station determines, based on a presence of the control channel on a specific component carrier, the indication of the resource set within which the allocated resource is located. 
Metoda iz patentnog zahtjeva 1 ili 2, gdje veliki broj skupova resursa sadrži veliki broj nositelja komponenti, prostore za pretragu kontrolnog kanala koji su distribuirani preko nositelja komponenti, i gdje sekundarna stanica (110) određuje iz mapiranja 1 prisustva kontrolnog kanala na specifičnom nositelju komponente indikaciju skupa resursa unutar kojeg je smješten alocirani resurs.
The process of claim 1 comprising increasing the ratio of sulfur to nitrogen in the first contact zone liquid effluent by adding ammonium thiosulfate. 
Postupak sukladno patentnom zahtjevu 1, naznačen time što povećava omjer sumpora prema dušiku u tekućem efluentu (6) prve kontraktne zone dodavanjem amonijevog tiosulfata.
The outer parts may be attached to the sides, respectively, by means of glue and/or welding and/or a snap-lock, or they may be integrated with the inner part by means of moulding, curling, bending or likewise. 
Vanjski dijelovi mogu biti pričvršćeni na svaku od strana pomoću ljepila i/ili zavarivanjem i/ili skočnim mehanizmom ili mogu biti spojeni s unutarnjim dijelom pomoću oblikovanih dijelova, zafrkanih dijelova, savijenih dijelova ili na sličan način.
The oil according to any of the claims 4 to 11 wherein, in the case a single flavouring is used, the amount of flavouring added to the product is comprised of between 0.02% and 0.1% by weight, preferably from 0.03% to 0.07% by weight, with respect to the weight of the other components. 
Ulje prema jednom od zahtjeva 4 do 11, naznačeno time, da je aromatski dodatak u sadržaju od 0,02 do 0,1 masenih %, poželjno od 0,03 do 0,07 masenih %, u odnosu na masu ostalih sastojaka, u slučaju uporabe samo jednog aromatskog dodatka u proizvodu.
75 wt.-% of the total weight of the preparation. 
75-% od ukupne mase pripravka.
optionally followed by a second oxidation to obtain the following compound: wherein: 
: i zatim, prema potrebi, drugoj oksidaciji, čime se dobije slijedeći spoj:
The selected amine is preferably used to salify at least 60% of the acid racemate used, i.e. in an amine/acid molar ratio equal to at least 0.6/1. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se navedeni amin koristi u molarnom odnosu amin/kiselina od najmanje 0,6/1.
A test band (4) for MIC (Minimal Inhibition Concentration) detection according to Claim 4, characterized by the interaction layer (2), wherein the cotton-polymer mixture fabric is a synthetic fabric having 50% or more cotton content. 
Test traka (4) za detekciju MIC prema patentnom zahtjevu 4, naznačena time što tkanine od pamučno-polimerne mješavine su sintetičke tkanine koje imaju 50% ili više sadržaja pamuka.
The protection factor of ascorbic acid against Candida reinfection was 46% in this investigation. 
Zaštitni faktor askorbinske kiseline protiv ponovne infekcije Candidom bio je 46 % u ovom istraživanju.
A composition according to claim 12, wherein the medicament is a vaccine. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 7 do 10, pri čemu je lijek cjepivo.
a pharmaceutically acceptable carrier; for use in a method of treatment eliciting an immune response, said method comprising administering an immunogenically effective amount of the composition to a mammalian subject such as a human, wherein the immune response is directed against the heterologous polypeptide, and wherein the route of administration is selected from the group consisting of oral, intranasal, and mucosal such as vaginal. 
(c) farmaceutski prihvatljivog nosača; za primjenu u postupku liječenja koji izaziva imunološki odgovor, pri čemu se spomenuti postupak sastoji od primjene imunogeno učinkovite količine vektora na sisara, npr. čovjeka, naznačen time, što je imunološki odgovor usmjeren protiv heterolognog polipeptida i naznačen time, što je put primjene odabran iz grupe koja se sastoji od oralne primjene, intranazalne primjene i mukozne primjene npr. vaginalne.
1-Chloro-4-(B-D-glucopyranos-1-yl)-2-[4-((S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene wherein at least 50% of said substance is present in the form of the crystalline form in accordance with claim 1 or 2. 
1-kloro-4<(B-D-glukopiranoza-1-il)-2-[4((S)-tetrahidrofuran-3-iloksi)-benzil]-benzen, naznačen time, da je barem 50% navedene supstancije prisutno u obliku kristaliničnog oblika u skladu sa zahtjevom 1 ili 2.
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same 
ANTITIJELA LAKOG LANCA MODIFICIRANA HISTIDINOM I GENETSKI MODIFICIRANI GLODAVCI ZA DOBIVANJE ISTIH
The aqueous pharmaceutical suspension according to claim 79, further comprising, by weight/volume (g/100 mL), 0.1% of titanium dioxide. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 89, naznačena time što dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,1 % titanijevog dioksida.